Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma

Celine Boutros; Etienne Rouleau; Michael Majer; Sergei Nikolaev; Caroline Robert

doi:10.1016/j.ejca.2021.03.022

Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma

Celine Boutros, Etienne Rouleau, Michael Majer, Sergei Nikolaev, Caroline Robert

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	130-132
Nombre de pages	3
journal	European Journal of Cancer
Volume	150
Les DOIs	https://doi.org/10.1016/j.ejca.2021.03.022
état	Publié - 1 juin 2021

Accès au document

10.1016/j.ejca.2021.03.022

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7ced7823f83444a982b528c2d3375395,

title = "Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma",

author = "Celine Boutros and Etienne Rouleau and Michael Majer and Sergei Nikolaev and Caroline Robert",

note = "Funding Information: C.B. reports being acted as a board advisor for BMS; reports being a speaker for Merck and has received travel fees from Amgen and Pfizer. C.R. reports being acted as a consultant of Amgen, BMS, GSK, Merck, Novartis and Roche. All the remaining authors have declared no competing interest. The Foundation Medicine{\textregistered} analysis was granted by Roche laboratory. This study has also received patient consent.",

year = "2021",

month = jun,

day = "1",

doi = "10.1016/j.ejca.2021.03.022",

language = "English",

volume = "150",

pages = "130--132",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. / Boutros, Celine; Rouleau, Etienne; Majer, Michael et al.
Dans: European Journal of Cancer, Vol 150, 01.06.2021, p. 130-132.

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

TY - JOUR

T1 - Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma

AU - Boutros, Celine

AU - Rouleau, Etienne

AU - Majer, Michael

AU - Nikolaev, Sergei

AU - Robert, Caroline

N1 - Funding Information: C.B. reports being acted as a board advisor for BMS; reports being a speaker for Merck and has received travel fees from Amgen and Pfizer. C.R. reports being acted as a consultant of Amgen, BMS, GSK, Merck, Novartis and Roche. All the remaining authors have declared no competing interest. The Foundation Medicine® analysis was granted by Roche laboratory. This study has also received patient consent.

PY - 2021/6/1

Y1 - 2021/6/1

UR - http://www.scopus.com/inward/record.url?scp=85104654378&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2021.03.022

DO - 10.1016/j.ejca.2021.03.022

M3 - Letter

C2 - 33901791

AN - SCOPUS:85104654378

SN - 0959-8049

VL - 150

SP - 130

EP - 132

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -